Neuroendocrine Tumors - Patient Reported Outcomes

Launched by UNIVERSITY OF IOWA · Sep 21, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how different treatments for neuroendocrine tumors (NETs) affect patients' lives. Neuroendocrine tumors include types that start in the digestive system (gastroenteropancreatic NETs or GEP-NETs) and the lungs. The researchers want to gather information directly from patients about their experiences, quality of life, and treatment choices. The goal is to improve how these treatments are given and to lessen any negative side effects. To do this, the study will involve around 2,515 patients aged 18 and older who were diagnosed with GEP-NET or lung NET between January 1, 2018, and September 30, 2024.

Participants in this trial will complete surveys either online or on paper over a period of 18 months. These surveys will ask about their treatment experiences and how they feel overall. The researchers will combine this survey information with patients' medical records to get a complete picture of their journey. If you are an adult diagnosed with a GEP-NET or lung NET during the specified time frame, you may be eligible to participate in this important study, which aims to enhance cancer care for all patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Adults age 18 years or older at time of NET diagnosis
• • (2) Diagnosis of GEP-NET or lung NET between 1/1/2018 and 09/30/2024, as evidenced by
• • (a) medical record information on diagnoses and/or medications and/or treatments and/or test results and/or clinical notes and/or procedures and/or encounters and/or tumor characteristics, and
• • (b) patient self-attestation of their diagnosis.
• Exclusion Criteria:
• • Any GEP-NET/Lung NET prior to 1/1/18, as evidenced by medical record information on diagnoses and/or medications and/or treatments and/or test results and/or clinical notes and/or procedures and/or encounters and/or tumor characteristics